Valerian

• Subjective sleep quality and mild insomnia (modest, mixed evidence)
• Sleep latency and time to fall asleep (self-reported)
• Anxiety and nervous tension (preliminary, heterogeneous)
• Menopausal sleep disturbance and hot-flash-related restlessness (small studies)
• Pre-operative or pre-procedural anxiety (preliminary)

Valerian (Valeriana officinalis) is a flowering perennial herb in the Caprifoliaceae family (formerly Valerianaceae) native to Europe and parts of Asia, cultivated and naturalized in temperate regions globally. Two thousand years of continuous European medicinal use document the plant in sleep and anxiety applications, Hippocrates and Galen described valerian as a sedative; medieval European herbalists used it for sleep, anxiety, and various nervous conditions; through the modern era valerian became among the most-used herbal sleep aids in Western markets. The medicinal portion is primarily the dried root and rhizome; fresh roots have minimal characteristic odor, but drying produces enzymatic conversion of valepotriates to isovaleric acid, the distinctive foul odor (variously described as old socks, wet dog, or aged cheese) that has become a defining organoleptic feature distinguishing valerian from related plants. The same isovaleric acid is responsible for the smell of old gym socks; this metabolic similarity is genuinely the chemical mechanism. The name Valeriana derives from Latin "valere" (to be strong/healthy) reflecting the historical medicinal positioning rather than the modern association with sedation. The active compound profile is complex and incompletely characterized. Three major compound classes have been identified: (1) sesquiterpenoids including valerenic acid, valeranone, and related compounds, valerenic acid is the most pharmacologically characterized compound with GABA-A receptor positive allosteric modulation; (2) valepotriates (iridoid compounds) which are pharmacologically active in fresh root but unstable, degrading during drying and storage to potentially toxic baldrinals, current commercial preparations typically contain minimal valepotriates; (3) various minor compounds including alkaloids, flavonoids, and amino acids (including GABA itself, though oral GABA absorption is poor). The pharmacology centers on GABA-A receptor positive allosteric modulation by valerenic acid, similar mechanism to benzodiazepines but substantially weaker affinity and clinical effect. Modulation of adenosine A1 receptors, serotonergic pathways, and possibly direct effects on GABA reuptake and synthesis have all been documented. The mechanism-effect translation is mechanistically coherent (GABA-A modulation supports sedation, anxiety reduction, and sleep effects) but clinical effect sizes are modest versus pharmaceutical alternatives (benzodiazepines, Z-drugs). The modern Western clinical evidence base is methodologically heterogeneous and methodologically modest. Bent 2006 American Journal of Medicine meta-analysis consolidated 16 RCTs of valerian for sleep, modest sleep quality improvements with substantial methodological heterogeneity, publication bias concerns, and effect sizes that varied substantially across trials. Subsequent systematic reviews have generally confirmed the modest effect-size assessment. The combination products with hops, lemon balm, and passionflower may produce better effects than valerian alone, some European pharmaceutical combinations (Sedariston, Hova) have substantial clinical use evidence. The EMA HMPC monograph (2006, updated 2016) supports valerian as traditional herbal medicinal product for relief of mild symptoms of mental stress and to aid sleep. The 2-3 week treatment duration for full effect distinguishes valerian from immediately-acting sleep medications; user expectation calibration about gradual onset matters substantially.

Standard valerian supplementation centers on 300-900mg/day of standardized extract (0.8% valerenic acid specification) for sleep applications. The standardized extract dose range corresponds to clinical trial protocols including Donath 2000 (600mg x 14 days) and various subsequent trials. For acute pre-sleep dosing, take 1-2 hours before bedtime; the onset is gradual and the effect develops over 2-3 weeks of chronic dosing for full effect. The expectation that valerian works immediately like a benzodiazepine is mismatched with the actual pharmacology, full sleep benefits typically require chronic dosing for 2-3 weeks. Take with or without food, absorption is acceptable either way. Combination products (valerian + hops, valerian + lemon balm, valerian + passionflower) may produce better effects than valerian alone for sleep and anxiety applications; verify individual herb doses in combination products. The Upper Limit (UL) has not been formally established; doses above 1500mg/day standardized extract produce diminishing returns and modest increased adverse effect frequency. The strong characteristic odor (isovaleric acid from drying enzymatic conversion) is the dominant practical limitation, capsule preparation addresses this for most users; tincture and tea forms expose users to substantial odor. Treatment duration matters: occasional acute pre-sleep use is reasonable for transient sleep difficulties; chronic dosing for 2-3 weeks for established sleep applications. Withdrawal effects (mild rebound insomnia, anxiety) have been reported after chronic high-dose use; taper rather than abrupt discontinuation reasonable for users on chronic doses. The mechanism through GABA-A positive allosteric modulation provides pharmacological credibility; the effect-size translation is modest versus benzodiazepines and Z-drugs.

Standardized extract range

300-900mg/day

Standardization specification

0.8% valerenic acid

Donath 2000 protocol

600mg x 14 days

Acute pre-sleep timing

1-2 hours before bedtime

Chronic effect onset

2-3 weeks for full effect

Combination products

Per individual herb dose

Whole root powder traditional

400-900mg/day

Tincture traditional

2-5ml, 1-3 times daily

• Standardized Valerian Extract (0.8% Valerenic Acid)

  Rating: gold

  European pharmaceutical-grade standardized extract specifying valerenic acid content. Used in essentially all major modern clinical trials including Donath 2000 polysomnography. Reasonable choice for clinical-grade supplementation. Premium pricing relative to non-standardized products.

• Valerian + Hops Combination (Sedariston, Hova)

  Rating: gold

  European pharmaceutical combination products combining valerian with hops (Humulus lupulus), possibly better clinical effects than valerian alone. Schmitz 1998 elderly sleep trial supports combination efficacy. Substantial European traditional and pharmaceutical use. Reasonable evidence-based combination for sleep applications.

• Valerian + Lemon Balm Combination

  Rating: good

  Common combination with Melissa officinalis (lemon balm) supported by some clinical evidence. Particularly used in anxiety-related sleep contexts. European traditional preparation.

• Valerian + Passionflower Combination

  Rating: good

  Combination with Passiflora incarnata supported by traditional use and modest clinical evidence. Less rigorously studied than valerian-hops combination.

• Valerian Tincture (Liquid Extract)

  Rating: good

  Traditional ethanolic extract preparation. Provides faster absorption than capsule forms; traditional European preparation. Strong characteristic odor, substantial palatability concern.

• Whole Valerian Root Powder

  Rating: good

  Whole dried valerian root and rhizome powder without extraction concentration. Active compound content varies substantially. Traditional preparation form; less reliable than standardized extracts for clinical effects. The strong characteristic odor limits palatability.

• Valerian Tea (Decoction)

  Rating: good

  Traditional valerian root tea preparation. Modest active compound extraction; the strong characteristic odor and bitter taste limit consumer adoption. Traditional European preparation.

• Generic Non-Standardized Valerian Products

  Rating: caution

  Products without specific valerenic acid content disclosure. Quality variability substantial; clinical effects unreliable due to active compound variation. Acceptable for traditional use; not preferred for therapeutic applications.

• Mild insomnia / sleep latency

  Strength of evidence for this group: modest

  Bent 2006 meta-analysis and EMA HMPC monograph support valerian for mild insomnia, particularly sleep latency improvement. Effect sizes consistently modest; reasonable component of sleep hygiene approach; not substitute for established sleep medications in moderate-severe insomnia. The 2-3 week treatment duration for full effect distinguishes valerian from immediate-acting sleep medications.

• Sleep maintenance / sleep quality

  Strength of evidence for this group: modest

  Donath 2000 polysomnography evidence supports modest improvements in sleep efficiency and slow-wave sleep over 2 weeks. Reasonable for users with sleep maintenance concerns; effect sizes modest versus pharmaceutical alternatives.

• Anxiety symptoms (preliminary)

  Strength of evidence for this group: cautious

  Andreatini 2002 valepotriate trial and traditional use support anxiety applications. Effect sizes preliminary; reasonable component of comprehensive anxiety management. Not substitute for established anxiety treatment in clinical anxiety disorders. Combination products (with hops, lemon balm) may produce better anxiety effects than valerian alone.

• Pre-procedural anxiety

  Strength of evidence for this group: cautious

  Preliminary evidence for acute valerian dosing 1-2 hours before stressful procedures (dental work, minor procedures). Reasonable acute use; coordinate with prescribing physician for combined use with anesthetic agents or pre-medication protocols.

• Restless legs syndrome

  Strength of evidence for this group: cautious

  Preliminary evidence for valerian in restless legs syndrome (RLS) symptom reduction. Effect sizes preliminary; reasonable adjunct to established RLS management. Specialist neurology coordination for established RLS.

• Menopausal sleep disturbance

  Strength of evidence for this group: cautious

  Preliminary evidence for valerian in menopausal sleep disturbance. Reasonable adjunct in comprehensive menopausal symptom management. Coordinate with gynecology for established menopausal symptom treatment.

• Children with ADHD-related sleep difficulties

  Strength of evidence for this group: cautious

  Preliminary European pediatric evidence and traditional pediatric use in some European traditions. Limited safety data for chronic pediatric use; specialist pediatric coordination essential. Not routine pediatric supplementation.

• Healthy adults (occasional sleep support)

  Strength of evidence for this group: cautious

  Reasonable component of comprehensive sleep hygiene approach for healthy adults with occasional sleep difficulties. Acceptable safety profile; modest effect-size calibration. Not substitute for addressing underlying sleep hygiene issues.

• Pregnancy and lactation

  Strength of evidence for this group: cautious

  Limited systematic safety data in pregnancy and lactation. Traditional European use includes pregnancy contexts but modern safety data is limited. Generally avoid by precautionary principle; coordinate with OB-GYN for chronic use.

• Established liver disease

  Strength of evidence for this group: cautious

  Hepatotoxicity case reports, predominantly involving combination products with other potentially hepatotoxic herbs (kava, comfrey, others). Valerian-specific hepatotoxicity remains debated. Reasonable caution in users with established liver disease; coordinate with hepatology.

• CNS depressant medication users

  Strength of evidence for this group: cautious

  Additive sedation with benzodiazepines, Z-drugs, alcohol, opioids, and other CNS depressants. Coordinate use; avoid concurrent acute use with alcohol or benzodiazepines.

• Hops (Humulus lupulus)

  Interaction: synergy

  The most-studied combination, Schmitz 1998 supported valerian-hops combination superiority over valerian alone in elderly insomnia. Mechanistically complementary GABA-A modulation. Sedariston, Hova, and similar European pharmaceutical combinations.

• Lemon Balm (Melissa officinalis)

  Interaction: synergy

  Common combination particularly for anxiety-related sleep disturbance. Mechanistically complementary, lemon balm provides distinct anxiolytic mechanism. Traditional European combination.

• Passionflower (Passiflora incarnata)

  Interaction: synergy

  Common combination for general sedation and sleep applications. Traditional use and modest clinical evidence support combination effectiveness.

• Magnesium

  Interaction: synergy

  Common combination in comprehensive sleep formulations. Mechanistically complementary, magnesium supports GABA function and sleep architecture through distinct mechanisms.

• L-Theanine

  Interaction: synergy

  Common combination for sleep and stress applications. Mechanistically complementary, L-theanine supports GABA-related calming and alpha brain wave activity.

• Benzodiazepines (Alprazolam, Lorazepam, Diazepam)

  Interaction: caution

  Additive GABA-A modulation; potential additive sedation and CNS depression. Coordinate with prescribing physician; generally avoid concurrent acute use.

• Z-Drugs (Zolpidem, Zaleplon, Eszopiclone)

  Interaction: caution

  Additive GABA-A modulation effects. Generally avoid concurrent acute use; coordinate with prescribing physician.

• Alcohol

  Interaction: caution

  Additive CNS depression. Avoid concurrent use; alcohol negates much of valerian's therapeutic effect while increasing adverse effect risk.

• Opioids

  Interaction: caution

  Additive CNS depression. Coordinate with prescribing physician; avoid concurrent acute use with opioid medications.

• Anti-Anxiety Medications (Buspirone)

  Interaction: caution

  Additive anxiolytic effects through complementary mechanisms. Coordinate with psychiatry for combined use.

• Hepatotoxic Medications

  Interaction: caution

  Valerian-associated hepatotoxicity case reports, predominantly involving combination products with other potentially hepatotoxic herbs. Reasonable caution about combination with acetaminophen at high doses, methotrexate, or other hepatotoxic medications. Hepatology coordination for chronic combined use.

• Anesthetic Agents

  Interaction: caution

  Potential additive sedation with pre-operative anesthesia. Disclose valerian use to anesthesiology; discontinue 1-2 weeks before elective procedures.

• Pregnancy

  Interaction: avoid

  Limited pregnancy safety data; generally avoid by precautionary principle. Some traditional European use in pregnancy but modern safety data is limited.

Look for: explicit Valeriana officinalis species specification; standardization to specific valerenic acid content (0.8% standard); appropriate dose for intended use (300-600mg standardized extract for sleep applications); combination products with hops, lemon balm, or passionflower for enhanced effects; USP or NSF third-party verification; reputable manufacturer with quality control disclosure. Avoid: non-standardized "valerian" products without valerenic acid specification (quality unreliable); products without species specification (potential V. wallichii or V. edulis substitution); products at very low cost (likely quality compromise); products from manufacturers without third-party testing disclosure; combination products with kava or comfrey (hepatotoxicity concerns); proprietary "sleep blends" obscuring valerian dose.

Research published from: Europe.

Valerian (Valeriana officinalis) has been used in European medicine for more than two thousand years. Hippocrates documented valerian as sedative and sleep aid in ancient Greek medicine; Galen (Roman, 2nd century CE) continued the medicinal documentation. The name Valeriana derives from Latin valere (to be strong/healthy), reflecting the historical positioning rather than the modern sedation focus. Medieval European herbalists including Hildegard von Bingen, John Gerard, and Nicholas Culpeper documented continuous use across sleep, anxiety, nervous disorders, and various other indications. The English name "all-heal" reflects the broad historical medicinal positioning. The modern European pharmaceutical era developed substantially through the 19th and 20th centuries. German pharmaceutical companies developed standardized valerian preparations through the late 19th century. The early 20th century saw substantial pharmaceutical use of valerian for "neurasthenia" and various nervous conditions. The development of synthetic sedatives (barbiturates in 1903, subsequently benzodiazepines from 1960) substantially reduced pharmaceutical valerian use through the 20th century, but valerian remained a substantial consumer herbal sleep aid throughout this period. The modern scientific era began with isolation and characterization of valerenic acid and related compounds in the 1980s-1990s. Houghton 1999 J Ethnopharmacology review consolidated the pre-modern and modern evidence base. Müller 2003 characterized valerenic acid as positive allosteric modulator at GABA-A receptors, mechanistic foundation for the modern understanding of valerian pharmacology. The modern clinical evidence era developed through systematic reviews and meta-analyses. Stevinson 2000 Sleep Med systematic review (9 RCTs) and Bent 2006 American Journal of Medicine meta-analysis (16 RCTs) consolidated the modest effect-size assessment that has remained the dominant evidence interpretation. Donath 2000 Pharmacopsychiatry polysomnography evidence provided objective sleep architecture documentation supporting the subjective clinical evidence. The European regulatory recognition era culminated in EMA HMPC monograph (2006, updated 2016) recognizing valerian as traditional herbal medicinal product for relief of mild symptoms of mental stress and to aid sleep. This represents one of the more rigorous regulatory recognitions of any herbal sleep aid in modern European context. The hepatotoxicity case series emerged in the 2000s with various reports, predominantly involving combination products (valerian + kava, valerian + skullcap, valerian + comfrey, others) where causation could not be specifically attributed to valerian. Trauner 2008 Phytomedicine review consolidated the pharmacovigilance assessment; valerian-specific hepatotoxicity has not been definitively established. The modern consumer market has remained substantial through the 2010s-2020s with valerian as among the most-used herbal sleep aids globally. The category has matured with standardized extract products, combination formulations, and pediatric-friendly preparations. The strong characteristic odor continues to limit some consumer adoption but capsule preparation addresses this for most users. The "natural alternative to sleeping pills" positioning remains prominent in consumer marketing despite the modest effect-size assessment in rigorous meta-analyses.

1. AntiquityHippocrates and Galen document valerian as sedative
2. Medieval eraHildegard von Bingen, Gerard, Culpeper European herbal tradition
3. 19th centuryGerman pharmaceutical valerian standardization develops
4. 1903Barbiturate introduction begins reducing pharmaceutical valerian use
5. 1960s-1980sBenzodiazepine era further reduces pharmaceutical valerian use
6. 1980s-1990sIsolation and characterization of valerenic acid
7. 1998Schmitz elderly valerian-hops combination trial
8. 1999Houghton comprehensive pharmacology review (J Ethnopharmacol)
9. 2000Stevinson systematic review (Sleep Med); Donath polysomnography evidence (Pharmacopsychiatry)
10. 2002Andreatini valepotriate anxiety trial
11. 2003Müller GABA-A receptor mechanism characterization; Hadley primary care review
12. 2006Bent meta-analysis (Am J Med); EMA HMPC monograph initial publication
13. 2007Taibi women's sleep trial
14. 2008Trauner hepatotoxicity case series review
15. 2016EMA HMPC monograph update

• Whether enhanced combination formulations (valerian-hops Sedariston, valerian-lemon balm, valerian-passionflower) produce clinically meaningful advantages over valerian alone, limited rigorous head-to-head comparison.
• Whether the modest effect-size assessment in modern Western RCTs reflects true effect size or methodological limitations of the trials, substantial heterogeneity across studies.
• Whether valerian has specific applications in anxiety disorders beyond sleep, preliminary evidence is suggestive but mainstream anxiety treatment hierarchy does not include valerian.
• Whether the valerian-hepatotoxicity case series signal will mature into formal clinical guidance or remain an unconfirmed pharmacovigilance signal, current data is methodologically limited.
• Whether the 2-3 week chronic dosing for full effect generalizes across applications or specific user populations.
• Whether the species variation (V. officinalis vs V. wallichii vs V. edulis) produces clinically meaningful differences, most clinical evidence is V. officinalis specifically.
• Whether the strong characteristic odor can be addressed through extraction methodology improvements without losing therapeutic activity.
• Whether genetic variants affecting GABA-A receptor pharmacology produce individual variability in valerian response.

Universally available globally as dietary supplement, food ingredient, and traditional herbal medicinal product. Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list. EMA HMPC 2006 (updated 2016) monograph recognizes Valeriana officinalis as traditional herbal medicinal product for relief of mild symptoms of mental stress and to aid sleep in European context. Pharmaceutical preparations: Sedariston, Hova, and similar European combination products are available by prescription or over-the-counter in select European markets. Major retail supplement brands include NOW Foods, Solgar, Nature's Way, Gaia Herbs, Nature's Bounty, Sundown Naturals, and most sleep-focused supplement manufacturers. Combination products (valerian + hops, valerian + lemon balm, valerian + passionflower) are widely available across major supplement brands. Traditional European preparations (valerian tea, tincture) are available from specialty herbal manufacturers. Production is widely distributed across European cultivation (particularly Germany, Hungary, Russia, France), China, and select North American sources. Quality variation across brands depends substantially on standardization to valerenic acid content; non-standardized products vary enormously in active compound content. Third-party testing (USP, NSF) provides standard quality assurance. The Valeriana genus includes multiple species (V. wallichii Indian valerian, V. edulis Mexican valerian, others); V. officinalis is the dominant European medicinal species with the substantial clinical evidence base. Species verification matters for standardized clinical applications.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Species

Valeriana officinalis (European common valerian)

Family

Caprifoliaceae (formerly Valerianaceae)

Active compounds

Valerenic acid, valepotriates, sesquiterpenoids

Primary characterized mechanism

GABA-A receptor positive allosteric modulation

Standardization

0.8% valerenic acid

Standard dose

300-600mg standardized extract daily

What follows is unfinished work on our side, not a finding about Valerian. A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• Where we land. We have not taken a position on this yet.